STRN-ALK Fusion in Lung Adenocarcinoma with Brain Metastasis Responded Well to Ensartinib: A Case Report

被引：5
|
作者：
Zhang, Linlin [1 ]
Xiao, Ping [1 ]
Meng, Fanlu [1 ]
Zhong, Diansheng [1 ]
机构：
[1] Tianjin Med Univ, Gen Hosp, Dept Med Oncol, Tianjin 300052, Peoples R China
来源：
CURRENT ONCOLOGY | 2022年 / 29卷 / 10期
基金：
中国国家自然科学基金;
关键词：
STRN-ALK fusion; lung adenocarcinoma; brain metastasis; ensartinib;
D O I：
10.3390/curroncol29100530
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
STRN-ALK fusion is a rare ALK rearrangement identified in non-small cell lung cancer (NSCLC) patients. Here, we reported a case of lung adenocarcinomas with brain metastasis, harboring STRN-ALK fusion, responded well to ensartinib. This case report could provide more information for the therapeutic strategy selecting of NSCLC patients harboring STRN-ALK fusion.
引用
收藏
页码：6749 / 6753
页数：5
相关论文
共 50 条
  • [1] Case Report: Ensartinib for gastric epithelioid inflammatory myofibrosarcoma with STRN-ALK fusion
    Li, Xiaoqing
    Zheng, Jingfan
    Li, Xinyi
    Chen, Yuyu
    Liu, Kang
    Li, Fangchao
    Lu, Zhong
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [2] Identification and Development of a Lung Adenocarcinoma PDX Model With STRN-ALK Fusion
    Ren, Hongzheng
    Hou, Xiaonan
    Eiken, Patrick W.
    Zhang, Jin
    Pierson, Karlyn E.
    Nair, Asha A.
    Davila, Jaime I.
    Kovarikova, Helena
    Jang, Jin Sung
    Johnson, Sarah H.
    Molina, Julian R.
    Marks, Randolph S.
    Yang, Ping
    Yi, Joanne E.
    Mansfield, Aaron S.
    Jen, Jin
    CLINICAL LUNG CANCER, 2019, 20 (02) : E142 - E147
  • [3] STRN-ALK Fusion in Lung Adenocarcinoma with Excellent Response Upon Alectinib Treatment: A Case Report and Literature Review
    Su, Cuiyun
    Jiang, Ya
    Jiang, Wei
    Wang, Huilin
    Liu, Sisi
    Shao, Yang
    Zhao, Wenhua
    Ning, Ruiling
    Yu, Qitao
    ONCOTARGETS AND THERAPY, 2020, 13 : 12515 - 12519
  • [4] Case Report: A rare case of non-small cell lung cancer with STRN-ALK fusion in a patient in very poor condition treated with first-line ensartinib
    Song, Guo-qiang
    Li, Yi-zhong
    Kong, Weiliang
    Hu, Guo-qiang
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [5] A Lung Adenocarcinoma with a STRN-ALK Rearrangement Was Poorly Responsive to Alectinib Treatment
    Iida, Y.
    Nakanishi, Y.
    Takahashi, N.
    Nishimaki, H.
    Nishizawa, T.
    Nakagawa, Y.
    Shimizu, T.
    Gon, Y.
    Masuda, S.
    Hashimoto, S.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1953 - S1953
  • [6] A rationale for the poor response to alectinib in a patient with adenocarcinoma of the lung harbouring a STRN-ALK fusion by artificial intelligence and molecular modelling: a case report
    Barberis, Massimo
    Rappa, Alessandra
    de Marinis, Filippo
    Pelosi, Giuseppe
    Rocco, Elena Guerini
    Zhan, Yinxiu
    Tiana, Guido
    TRANSLATIONAL LUNG CANCER RESEARCH, 2024, 13 (12) : 3807 - 3814
  • [7] Coexistence of a secondary STRN-ALK, EML4-ALK double-fusion variant in a lung adenocarcinoma patient with EGFR mutation: a case report
    Zeng, Qian
    Gao, Han
    Zhang, Longdan
    Qin, Shouming
    Gu, Yongyao
    Chen, Quanfang
    ANTI-CANCER DRUGS, 2021, 32 (08) : 890 - 893
  • [8] Case Report: Identification of Two Rare Fusions, PDK1-ALK and STRN-ALK, That Coexist in a Lung Adenocarcinoma Patient and the Response to Alectinib
    Zeng, Hao
    Li, Yalun
    Wang, Ye
    Huang, Meijuan
    Zhang, Yan
    Tian, Panwen
    Li, Weimin
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [9] Remarkable response to alectinib for metastatic papillary thyroid cancer with STRN-ALK fusion: A case report
    Zhu, Lucheng
    Ma, Shenglin
    Xia, Bing
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [10] Case Report of Non-Small Cell Lung Cancer with STRN-ALK Translocation: A Nonresponder to Alectinib
    Nakanishi, Yoko
    Masuda, Shinobu
    Iida, Yuko
    Takahashi, Noriaki
    Hashimoto, Shu
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (12) : E202 - E204
12345